NCT03974022 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 14
- group Id
- BG007
- value
- 14
- group Id
- BG008
- value
- 7
- group Id
- BG009
- value
- 31
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 5
- units
- Participants
- groups
- description
- Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy. Patients received a single dose of 50 mg sunvozertinib, followed by a 7-day washout period. Then, they received 50 mg sunvozertinib once daily continuously.
- id
- BG000
- title
- Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg
- description
- Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy. Patients received a single dose of 100 mg sunvozertinib, followed by a 7-day washout period. Then, they received 100 mg sunvozertinib once daily continuously.
- id
- BG001
- title
- Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg
- description
- Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy. Patients received a single dose of 200 mg sunvozertinib, followed by a 7-day washout period. Then, they received 200 mg sunvozertinib once daily continuously.
- id
- BG002
- title
- Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg
- description
- Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy. Patients received a single dose of 300 mg sunvozertinib, followed by a 7-day washout period. Then, they received 300 mg sunvozertinib once daily continuously.
- id
- BG003
- title
- Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg
- description
- Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy. Patients received a single dose of 400 mg sunvozertinib, followed by a 7-day washout period. Then, they received 400 mg sunvozertinib once daily continuously.
- id
- BG004
- title
- Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg
- description
- Patients with EGFR or HER2 exon20ins, previously treated with at least one line of systemic therapy. Patients received sunvozertinib 200 mg once daily dosing in the fasted state continuously.
- id
- BG005
- title
- Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State
- description
- Patients with EGFR or HER2 exon20ins, previously treated with at least one line of systemic therapy. Patients received sunvozertinib 300 mg once daily dosing in the fasted state continuously.
- id
- BG006
- title
- Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State
- description
- Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy. Patients received sunvozertinib 200 mg once daily dosing with a low-fat meal continuously.
- id
- BG007
- title
- Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal
- description
- Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy. Patients received sunvozertinib 300 mg once daily dosing with a low-fat meal continuously.
- id
- BG008
- title
- Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal
- description
- Patients with EGFR exon20ins, treatment naïve. Patients received sunvozertinib 300 mg once daily dosing with a low-fat meal continuously.
- id
- BG009
- title
- Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal
- description
- Patients with EGFR exon20ins, were refractory to, relapsed from, or intolerant to previous amivantamab treatment. No patient was enrolled into this cohort.
- id
- BG010
- title
- Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg
- description
- Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy. Patients were randomized at a 1:1 ratio to receive a single dose of sunvozertinib 300 mg under the High-Fat Meal condition, followed by a 7-day washout and crossed to receive a single dose of sunvozertinib 300 mg under the Fasted condition, followed by a 7-day washout. Then patients received sunvozertinib 300 mg once daily continuously.
- id
- BG011
- title
- Part A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then Fasted
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 38
- upper Limit
- 72
- value
- 48.0
- group Id
- BG001
- lower Limit
- 48
- upper Limit
- 83
- value
- 62.0
- group Id
- BG002
- lower Limit
- 55
- upper Limit
- 74
- value
- 57.0
- group Id
- BG003
- lower Limit
- 57
- upper Limit
- 82
- value
- 64.0
- group Id
- BG004
- lower Limit
- 48
- upper Limit
- 85
- value
- 63.5
- group Id
- BG005
- lower Limit
- 41
- upper Limit
- 83
- value
- 61
- group Id
- BG006
- lower Limit
- 41
- upper Limit
- 76
- value
- 62.5
- group Id
- BG007
- lower Limit
- 34
- upper Limit
- 73
- value
- 60.5
- group Id
- BG008
- lower Limit
- 38
- upper Limit
- 73
- value
- 64
- group Id
- BG009
- lower Limit
- 37
- upper Limit
- 96
- value
- 61
- group Id
- BG011
- lower Limit
- 39
- upper Limit
- 82
- value
- 44.0
- group Id
- BG012
- lower Limit
- 55
- upper Limit
- 78
- value
- 65.0
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 9
- group Id
- BG008
- value
- 2
- group Id
- BG009
- value
- 13
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 4
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 5
- group Id
- BG008
- value
- 5
- group Id
- BG009
- value
- 18
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 1
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 9
- group Id
- BG007
- value
- 13
- group Id
- BG008
- value
- 7
- group Id
- BG009
- value
- 23
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 1
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 5
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 4
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- No patient was enrolled in Part A dose expansion cohort 6 due to conflict with enrollment of Part B.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 14
- group Id
- BG007
- value
- 14
- group Id
- BG008
- value
- 7
- group Id
- BG009
- value
- 31
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 5
- units
- Participants
- groups
- description
- Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy. Patients received a single dose of 50 mg sunvozertinib, followed by a 7-day washout period. Then, they received 50 mg sunvozertinib once daily continuously.
- id
- BG000
- title
- Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg
- description
- Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy. Patients received a single dose of 100 mg sunvozertinib, followed by a 7-day washout period. Then, they received 100 mg sunvozertinib once daily continuously.
- id
- BG001
- title
- Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg
- description
- Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy. Patients received a single dose of 200 mg sunvozertinib, followed by a 7-day washout period. Then, they received 200 mg sunvozertinib once daily continuously.
- id
- BG002
- title
- Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg
- description
- Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy. Patients received a single dose of 300 mg sunvozertinib, followed by a 7-day washout period. Then, they received 300 mg sunvozertinib once daily continuously.
- id
- BG003
- title
- Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg
- description
- Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy. Patients received a single dose of 400 mg sunvozertinib, followed by a 7-day washout period. Then, they received 400 mg sunvozertinib once daily continuously.
- id
- BG004
- title
- Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg
- description
- Patients with EGFR or HER2 exon20ins, previously treated with at least one line of systemic therapy. Patients received sunvozertinib 200 mg once daily dosing in the fasted state continuously.
- id
- BG005
- title
- Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State
- description
- Patients with EGFR or HER2 exon20ins, previously treated with at least one line of systemic therapy. Patients received sunvozertinib 300 mg once daily dosing in the fasted state continuously.
- id
- BG006
- title
- Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State
- description
- Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy. Patients received sunvozertinib 200 mg once daily dosing with a low-fat meal continuously.
- id
- BG007
- title
- Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal
- description
- Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy. Patients received sunvozertinib 300 mg once daily dosing with a low-fat meal continuously.
- id
- BG008
- title
- Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal
- description
- Patients with EGFR exon20ins, treatment naïve. Patients received sunvozertinib 300 mg once daily dosing with a low-fat meal continuously.
- id
- BG009
- title
- Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal
- description
- Patients with EGFR exon20ins, were refractory to, relapsed from, or intolerant to previous amivantamab treatment. No patient was enrolled into this cohort.
- id
- BG010
- title
- Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg
- description
- Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy. Patients were randomized at a 1:1 ratio to receive a single dose of sunvozertinib 300 mg under the High-Fat Meal condition, followed by a 7-day washout and crossed to receive a single dose of sunvozertinib 300 mg under the Fasted condition, followed by a 7-day washout. Then patients received sunvozertinib 300 mg once daily continuously.
- id
- BG011
- title
- Part A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then Fasted
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 38
- upper Limit
- 72
- value
- 48.0
- group Id
- BG001
- lower Limit
- 48
- upper Limit
- 83
- value
- 62.0
- group Id
- BG002
- lower Limit
- 55
- upper Limit
- 74
- value
- 57.0
- group Id
- BG003
- lower Limit
- 57
- upper Limit
- 82
- value
- 64.0
- group Id
- BG004
- lower Limit
- 48
- upper Limit
- 85
- value
- 63.5
- group Id
- BG005
- lower Limit
- 41
- upper Limit
- 83
- value
- 61
- group Id
- BG006
- lower Limit
- 41
- upper Limit
- 76
- value
- 62.5
- group Id
- BG007
- lower Limit
- 34
- upper Limit
- 73
- value
- 60.5
- group Id
- BG008
- lower Limit
- 38
- upper Limit
- 73
- value
- 64
- group Id
- BG009
- lower Limit
- 37
- upper Limit
- 96
- value
- 61
- group Id
- BG011
- lower Limit
- 39
- upper Limit
- 82
- value
- 44.0
- group Id
- BG012
- lower Limit
- 55
- upper Limit
- 78
- value
- 65.0
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 9
- group Id
- BG008
- value
- 2
- group Id
- BG009
- value
- 13
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 4
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 5
- group Id
- BG008
- value
- 5
- group Id
- BG009
- value
- 18
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 1
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 9
- group Id
- BG007
- value
- 13
- group Id
- BG008
- value
- 7
- group Id
- BG009
- value
- 23
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 1
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 5
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 4
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- No patient was enrolled in Part A dose expansion cohort 6 due to conflict with enrollment of Part B.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle